Jump to:
Ryan Kramer joined Ropes & Gray’s corporate department in 2022. Ryan primarily practices in the intellectual property transactions group, advising life sciences clients on a broad range of strategic transactions, including complex licensing arrangements, collaborations, mergers & acquisitions, and royalty monetization transactions.
During law school, Ryan served as a notes editor for the Boston University Law Review and as a lawyering fellow in the school’s first-year legal writing program. He also served as the networking director for the Health Law Association and worked as a research assistant focusing on consumer protection and privacy law.
Experience
- Advised Agios Pharmaceuticals in an exclusive global license agreement with South Korea-based Oscotec for Cevidoplenib, a Phase 2 oral spleen tyrosine kinase inhibitor to treat immune thrombocytopenia, in a deal worth up to $665 million.
- Advised Madrigal Pharmaceuticals in an exclusive global license agreement with Arrowhead Pharmaceuticals for its clinical stage siRNA candidate ARO-PNPLA3 for the treatment of MASH, in a deal worth up to $1 billion.
- Advised Madrigal Pharmaceuticals in an exclusive global license agreement with Suzhou Ribo Life Sciences Co. and its subsidiary Ribocure Pharmaceuticals AB for six preclinical small interfering RNA (siRNA) programs to treat MASH liver disease in a deal worth up to $4.4 billion.
- Advised Madrigal Pharmaceuticals in an exclusive global license agreement with Pfizer for ervogastat, a Phase 2 oral therapy that could be combined to enhance the clinical effects of Madrigal’s FDA approved drug Rezdiffra, for treatment of a serious liver disease called metabolic dysfunction-associated steatohepatitis (MASH).
- Advised Viridian Therapeutics in securing up to $300 million in funding from DRI Healthcare Acquisitions in exchange for a royalty on U.S. net sales of Viridian’s thyroid eye disease therapies veligrotug and VRDN-003.
- Advised Viridian Therapeutics in an exclusive license and collaboration agreement with Kissei Pharmaceutical to develop and market thyroid eye disease therapies veligrotug and VRDN-003 in Japan.
- Advised Madrigal Pharmaceuticals in an exclusive global license agreement with CSPC Pharmaceutical Group Limited for SYH2086, a preclinical oral small molecule GLP-1 receptor agonist, in a transaction worth up to $2 billion.
- Advised Novo Nordisk in an exclusive license agreement with The United Laboratories to develop, manufacture, and commercialize United’s UBT-251, a triple agonist of the receptors for GLP-1, GIP, and glucagon, for the treatment of diabetes, obesity, and other diseases globally, excluding Greater China, in a transaction worth up to $2 billion.
- Represented Sarepta Therapeutics in a transformational global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple siRNA programs worth up to $11.35 billion.
- Represented Novo Nordisk in a worldwide collaboration with Neomorph Inc. worth up to $1.46 billion to discover, develop and commercialize molecular glue degraders for multiple targets.
- Advised ImmunoGen, Inc. on intellectual property matters related to its $10.1 billion sale to AbbVie Inc.
- Represented Regeneron Pharmaceuticals in its acquisition of 2seventy Bio Inc.’s oncology and autoimmune programs as part of its newly launched R&D unit Regeneron Cell Medicines.
- Represented a multinational pharmaceutical company in a strategic transaction with a Chinese biotechnology company to develop potential first-in-class peptide therapeutics worth up to $3.5 billion.
- Represented a leading investment management firm in the sale of its royalty interest in a therapy for the treatment of cardiovascular disease.
- Represented the lead underwriters in the initial public offering of Loar Holdings Inc.